多模态脑网络的深度图学习定义重性抑郁障碍的治疗预测特征
基于EMBARC试验中130例舍曲林和135例安慰剂治疗的重性抑郁障碍患者,研究利用静息态功能磁共振与脑电连接数据构建图神经网络深度学习框架,预测个体症状变化;模型预测R²在舍曲林组为0.24、安慰剂组为0.20,并识别出两组各自的关键脑区与网络特征。
要点
- 图神经网络整合功能磁共振与脑电连接数据,预测舍曲林组R²=0.24、安慰剂组R²=0.20。
- 舍曲林反应关键脑区:功能磁共振为颞下回,脑电为后扣带回。
- 安慰剂反应关键脑区:功能磁共振为楔前叶,脑电为辅助运动区。
核心结论
- 整合功能磁共振与脑电建立的多模态脑网络特征可预测重性抑郁障碍患者对舍曲林和安慰剂的个体化反应,并提供可解释的神经环路模式,可能指导未来靶向干预。
研究设计与样本
- 分析EMBARC研究中130例接受舍曲林治疗和135例接受安慰剂治疗的重性抑郁障碍患者的静息态功能磁共振与脑电连接数据。
- 开发基于图神经网络的深度学习框架,整合数据增强的连接与跨模态相关性,通过揭示多模态脑网络特征预测个体症状变化。
主要发现
- 模型预测精度:舍曲林组R²=0.24,安慰剂组R²=0.20。
- 模型在仅使用脑电数据迁移预测时也表现出潜力。
- 预测舍曲林反应的关键脑区包括颞下回(功能磁共振)和后扣带回(脑电)。
- 预测安慰剂反应的关键脑区包括楔前叶(功能磁共振)和辅助运动区(脑电)。
- 两种模态均识别出颞上回和后扣带回对舍曲林反应显著,而前扣带回和中央后回为安慰剂组的共同预测因子;额顶控制网络、腹侧注意网络、背侧注意网络和边缘网络的变化与重性抑郁障碍治疗显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major depressive disorder (MDD) presents a substantial health burden with low treatment response rates. Predicting antidepressant efficacy is challenging due to MDD's complex and varied neuropathology. Identifying biomarkers for antidepressant treatment requires thorough analysis of clinical trial data. Multimodal neuroimaging, combined with advanced data-driven methods, can enhance our understanding of the neurobiological processes influencing treatment outcomes. To address this, we analyzed resting-state fMRI and EEG connectivity data from 130 patients treated with sertraline and 135 patients with placebo from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study. A deep learning framework was developed using graph neural networks to integrate data-augmented connectivity and cross-modality correlation, aiming to predict individual symptom changes by revealing multimodal brain network signatures. The results showed that our model demonstrated promising prediction accuracy, with an R2 value of 0.24 for sertraline and 0.20 for placebo. It also exhibited potential in transferring predictions using only EEG. Key brain regions identified for predicting sertraline response included the inferior temporal gyrus (fMRI) and posterior cingulate cortex (EEG), while for placebo response, the precuneus (fMRI) and supplementary motor area (EEG) were critical. Additionally, both modalities identified the superior temporal gyrus and posterior cingulate cortex as significant for sertraline response, while the anterior cingulate cortex and postcentral gyrus were common predictors in the placebo arm. Additionally, variations in the frontoparietal control, ventral attention, dorsal attention, and limbic networks were notably associated with MDD treatment. By integrating fMRI and EEG, our study established novel multimodal brain network signatures to predict individual responses to sertraline and placebo in MDD, providing interpretable neural circuit patterns that may guide future targeted interventions. Trial Registration: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC) ClinicalTrials.gov Identifier: NCT#01407094.
引用
- Jiao Y, Zhao K, Wei X, et al. Deep graph learning of multimodal brain networks defines treatment-predictive signatures in major depression. Mol Psychiatry. 2025. PMID: 40164695. doi:10.1038/s41380-025-02974-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。